News for Healthier Living

Cetuximab Outperforms Durvalumab in Treatment of Head and Neck Cancers

The standard treatment for head and neck cancer, cisplatin, can't be given to some patients due to pre-existing conditions. A new study compares the efficacy of two alternatives: cetuximab, a monoclonal antibody, and durvalumab, an immune checkpoint inhibitor.

November 21, 2024


November 21 2024

November 20 2024

November 19 2024

November 18 2024

November 17 2024

November 16 2024

November 15 2024

November 14 2024

November 13 2024

November 12 2024

November 11 2024

November 10 2024

November 9 2024

November 8 2024